2010 is ending and 2011 is about to begin. It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there have been far fewer ten-baggers with more than 1,000% gains in 2010. Still, we have gone through a review of the “big biotechs” with a market cap cut off of $1 billion or higher. What we found was a series of the big 2010 winners and we also found which of the big biotech players may have the most upside ahead in 2011. Biohealth Investor has two separate groups reviewing those with the most implied upside for 2011 and also another showing those with best performance so far this year in 2010.
The big winners of 2010 have so far included shares of Illumina Inc. (NASDAQ: ILMN), InterMune Inc. (NASDAQ: ITMN), Incyte Corporation (NASDAQ: INCY), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM). We have taken a look at what has driven the gains as well as what the prospects are for 2011 and beyond. FULL REPORT
Dendreon Corporation (NASDAQ: DNDN) appears to have the most implied upside of the $1 billion and higher catgory, but others included are Amgen Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Human Genome Sciences, Inc. (NASDAQ: HGSI), Incyte Corporation (NASDAQ: INCY), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). The full list is available showing the implied upside and we have added color and commentary on each. FULL REPORT
Stay tuned for many more sector updates in many sectors with winners of 2010 and the outlook for 2011 and beyond!
JON C. OGG